微生态制剂对肝硬化患者肠道菌群及内毒素水平干预疗效观察(1)
 |
| 第1页 |
参见附件(2042KB，3页)。
【摘要】 目的 探讨微生态制剂对肝硬化患者肠道菌群、内毒素水平的干预作用及疗效。
方法选择肝硬化患者57例，另选取24例健康体检者作为健康组，将57例肝硬化患者随机分为对照组25例，观察组32例，两组均采用常规护肝利尿治疗，观察组在此基础上，加用双歧杆菌三联活菌胶囊治疗8周，分别测定治疗前各组及治疗后两疾病组肠道10种细菌菌落数和内毒素水平。并对比两疾病组治疗前后并发症的变化情况。结果 治疗前肝硬化患者的内毒素水平显著高于健康体检者(P<0.01)，肠道菌群中的双歧杆菌、乳杆菌、肠杆菌显著低于健康体检者(P<0.05或0.01)，葡萄球菌、梭菌显著高于健康体检者(P<0.01)。治疗前两疾病组内毒素水平及各肠道菌群菌落数比较差异无统计学意义(P均>0.05)，治疗后对照组内毒素水平无显著变化(P>0.05)，观察组内毒素水平显著低于治疗前(P<0.01)；对照组中肠杆菌、真杆菌较治疗前显著下降(P<0.05或0.01)，观察组中肠杆菌、双歧杆菌、乳杆菌、拟杆菌较治疗前显著升高，葡萄球菌、梭菌较治疗前显著降低(P<0.05或0.01)，其中治疗后观察组的双歧杆菌、乳杆菌菌落数显著高于对照组(P<0.05或0.01)。治疗前后比较，观察组的并发症发生率显著降低(P<0.01)，对照组无改变。结论微生态制剂能调节肠道菌群状态，提高肠道有益菌如双歧杆菌含量，降低内毒素水平，对降低肝硬化并发症发生率、改善预后具有重要的临床意义。
【关键词】 内毒素；肠道菌群；微生态制剂；肝硬化
文章编号：1003-1383(2010)06-0659-03 中图分类号：R 575.2文献标识码：A
doi:10.3969/j.issn.1003-1383.2010.06.003
Study on the effect of microecologial agents in the intestinal flora and endotoxin level of patients with liver cirrhosis
CHEN Yuping,ZHONG Zhuanhua,LIANG Yuehuan,WANG An
(The People's Hospital of Zhuhai,Guangdong Zhuhai,519000,China)
【Abstract】 Objective To investigate the effect of microecological agents on the intestinal flora and endotoxin level of patients with liver cirrhosis.
Methods 57 patients with liver cirrhosis and 24 healthy participants were chosen. 57 patients with cirrhosis were randomly divided into control group(25 cases) and treatment group(32 cases)，both groups were treated with conventional diuretic liver,the treatment group was added bifidobacterium triple viable capsule for 8 weeks.10 colonies number and endotoxin levels were measured in three groups pre and post treatment.
Results Endotoxin levels in cirrhotic patients was significant higher than healthy group (P<0.01),the colonies number of bifidobacteria,Lactobacillus and enterobacteriaceae in the intestinal flora were significant lower than healthy group(P<0.05 or 0.01),the colonies number of staphylococcus aureus and Fusobacterium was significant higher than healthy group before treatment(P<0 ......
您现在查看是摘要介绍页，详见PDF附件(2042KB，3页)。